Roger Echols, MD

Consultant
Infectious Disease Drug Development Consulting LLC

Disclosure: Shionogi Inc. (Individual(s) Involved: Self): Consultant

Presentation(s):

• 164 - in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018

  Oral Abstract

• 165 - Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study

  Oral Abstract